Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

The article discusses a retrospective study which examines the outcomes of patients who required early discontinuation of tacrolimus and sirolimus, and were given with mycophenolate mofetil (MMF)-based salvage as acute graft-versus-host disease (GVHD) prophylaxis. It indicates the feasibility of prophylaxis for patients with high risk for toxicities. It shows that overall survival (OS) and nonrelapse mortality (NRM) rates were in an acceptable range given the high-risk nature of patients.